<DOC>
	<DOC>NCT02005848</DOC>
	<brief_summary>A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Study Evaluating the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes. The study objectives are: - To assess the efficacy of intravenous AAT in treatment of new onset Type 1 Diabetes - To assess the safety and tolerability of intravenous AAT in new onset Type 1 Diabetes pediatric and young adult population.</brief_summary>
	<brief_title>Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Main Subject (or parent/guardian) willing and able to sign an informed consent Age 825 (inclusive) years Recently diagnosed with T1DM Basal Cpeptide ≥ 0.2 pmol/mL Positive for at least one diabetesrelated autoantibody Ability and consent to comply with completion of patient diary No significant abnormalities in serum hematology, serum chemistry No significant abnormalities in urinalysis No significant abnormalities in ECG For women of child bearing potential, nonpregnant, nonlactating female patients Main IgA deficient subjects Subjects who have received an active/ live virus vaccine within 4 weeks of the screening date Subjects who have received treatment with corticosteroid medication within 2 months prior to screening or any immunosuppressant or cytostatic agent within 6 months prior to screening Individuals with a history of severe immediate hypersensitivity reactions, including anaphylaxis, to plasma products Clinically significant intercurrent illnesses Pregnant or lactating women Current use of any medication known to influence glucose tolerance Current or prior (within the last 60 days prior to screening visit) use of metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPPIV inhibitors or amylin.</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Type-1 Diabetes</keyword>
	<keyword>T1D</keyword>
	<keyword>Diabetes Mellitus</keyword>
</DOC>